M. Schmidt1
, E. Svobodova2
, V. Semanekova2
, M. Klabanova3
, J.
Mares2
1
Urology Clinic, 2nd Medical Faculty, Prague, Czech
Republic, 2
Institute of Biology and Medical Genetics, 2nd
Medical Faculty, Prague, Czech Republic, 3
Diana Lucina,
Prague, Czech Republic
Abstracts from the 51st European Society of Human Genetics Conference: Posters 465
The general diagnosis for metastatic CaP remains poor and
locally advanced disease is difficult to treat successfully.
Except the PSA, no specific diagnostic test for CaP is
currently available. SHB protein takes part in regulation
system of apoptosis, angiogenesis and cell cycle. Reduced
tumour growth in vivo and increased c-Abl activity in PC3
prostate cancer cells overexpressing SHB was described in
mice. In this first-ever study evaluating SHB expression in
human prostate, transcription levels of SHB in prostate
cancer and benign prostate hyperplasia was compared.
Isolation of total RNA from prostate tissue in 127 patients
with histologically proved prostate cancer and 55 patients
with benign prostate hyperplasia was performed. After
qRT-PCR, comparisons of transcriptional levels in prostate
cancer and BPH and in prostate cancer groups classified by
staging, Gleason score, age and PSA were evaluated.
Underexpression of SHB in prostate cancer tissue comparing to benign prostate hyperplasia (p< 0.001) and decreased
expression in locally advanced disease (T2 v.s. T3-4)
(p = 0.0066) were detected. There were no differences in
comparison of the groups distributed by Gleason score, age
and PSA. SHB was underexpressed in prostate cancer tissue
compared to BPH and its expression was lower in locally
advanced tumours. This data may be used to make the
diagnosis of prostate cancer more precise. Research was
supported by Diana Lucina, GAUK 200 090 and IG
00064203.
M. Schmidt: None. E. Svobodova: None. V. Semanekova: None. M. Klabanova: None. J. Mares: None.